LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced today that Researchers at National Jewish Medical & Research Center and the University of Colorado Health Sciences in Denver, Colorado have been awarded a 5 year Center grant from the National Institutes of Health (NIH) Countermeasures Against Chemical Threats (CounterACT) Research Network to support the development of compounds to protect and treat lung and skin injury associated with mustard gas exposure. One of the lead compounds being tested in studies to be conducted this summer is Aeolus Pharmaceuticals’ AEOL 10150.
